Dyad Medical Secures FDA Clearance For Echo:Prio Cardiac Imaging Analysis Platform

Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis, announced that the U.S. Food and Drug Administration (FDA) has cleared its Echocardiogram application called Echo:Prio through the 510(k) pathway. Echo:Prio, part of the complete cardiac platform named Libby, offers fast, data-driven image analysis of echocardiogram images. It is an important decision-making support tool for index quantification of cardiac function saving the clinician time in diagnosis and treatment-decision making. Echocardiograms are often the first step in diagnosing and developing a treatment plan for heart disease. The heart is the only organ in constant movement as it pumps blood throughout the body.